MannKind (NASDAQ:MNKD) 概述 2026 年 Furoscix 营收目标为 1.1 亿至 1.2 亿美元，ReadyFlow 将于数周内发货
· seekingalpha.com
MannKind (MNKD) 2026 年第二季度收益电话会议回顾：Afrezza 儿科使用情况、Furoscix ReadyFlow 发布时间、营收组合、现金流及风险——立即阅读。
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...